• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Tempus AI Inc.

    8/8/24 4:38:12 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology
    Get the next $TEM alert in real time by email
    SC 13G 1 formsc13g.htm Proof -

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

     

     

    Tempus AI, Inc.

    (Name of Issuer)

     

    Class A Common Stock

    (Titles of Class of Securities)

     

    71535D106

    (CUSIP Number)

     

    June 30, 2024

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐ Rule 13d-1(b)

     

    ☐ Rule 13d-1(c)

     

    ☒ Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     
     

     

    1  

    Name of Reporting Person

     

    BK TL21 LLC

    2  

    Check the Appropriate Box if a Member of a Group

    (a) ☐ (b) ☐

     

    3  

    SEC Use Only

     

    4  

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares Beneficially

    Owned by

    Each

    Reporting

    Person

    With:

      5  

    Sole Voting Power

     

    0

      6  

    Shared Voting Power

     

    16,560,249

      7  

    Sole Dispositive Power

     

    0

      8  

    Shared Dispositive Power

     

    16,560,249

    9  

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    16,560,249

    10  

    Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares

     

    ☐

    11  

    Percent of Class Represented by Amount in Row 9

     

    11.1%1

    12  

    Type of Reporting Person

     

    CO

     

     

    1 Based on 149,274,923 shares outstanding as reported the issuer’s Form 10-Q for the quarterly period ended June 30, 2024 filed with the SEC on August 6, 2024.

     

     
     

     

    1  

    Name of Reporting Person

     

    Bradley Keywell

    2  

    Check the Appropriate Box if a Member of a Group

    (a) ☐ (b) ☐

     

    3  

    SEC Use Only

     

    4  

    Citizenship or Place of Organization

     

    United States

    Number of

    Shares Beneficially

    Owned by

    Each

    Reporting

    Person

    With:

      5  

    Sole Voting Power

     

    16,560,249

      6  

    Shared Voting Power

     

    0

      7  

    Sole Dispositive Power

     

    0

      8  

    Shared Dispositive Power

     

    16,560,249

    9  

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    16,560,249

    10  

    Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares

     

    ☐

    11  

    Percent of Class Represented by Amount in Row 9

     

    11.1%2

    12  

    Type of Reporting Person

     

    IN

     

     

    2 Based on 149,274,923 shares outstanding as reported the issuer’s Form 10-Q for the quarterly period ended June 30, 2024 filed with the SEC on August 6, 2024.

     

     
     

     

    Item 1(a). Name of Issuer:

     

    Tempus AI, Inc.

     

    Item 1(b). Address of Issuer’s Principal Executive Offices:

     

    600 West Chicago Avenue, Suite 510

     

    Chicago, Illinois 60654

     

    Item 2(a). Name of Person Filing:

     

    This Schedule 13G is being filed by the following persons (each, a “Reporting Person”):

     

    i. BK TL21 LLC (“BK”)

     

    ii. Bradley Keywell (“Keywell”)

     

    Item 2(b). Address of Principal Business Office or, if none, Residence:

     

    The principal business address of each of the Reporting Persons is:

     

    4603 Franklin Pike

     

    Nashville, Tennessee 37220

     

    Item 2(c). Citizenship:

     

    BK is organized under the laws of the State of Delaware.

     

    Keywell is a citizen of the United States.

     

    Item 2(d). Titles of Classes of Securities:

     

    Class A Common Stock, par value $0.0001 per share (the “Shares”).

     

    Item 2(e). CUSIP Number:

     

    71535D106

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    Not applicable.

     

    Item 4. Ownership

     

    (a) Amount beneficially owned:

     

    See response to Item 9 on each Reporting Person’s cover page.

     

    (b) Percent of class:

     

    See response to Item 11 on Reporting Person’s cover page.

     

    (c) Number of shares as to which such person has:

     

    (i) Sole power to vote or to direct the vote:

     

    See response to Item 5 on each Reporting Person’s cover page.

     

     
     

     

    (ii) Shared power to vote or to direct the vote:

     

    See response to Item 6 on each Reporting Person’s cover page.

     

    (iii) Sole power to dispose or to direct the disposition of:

     

    See response to Item 7 on each Reporting Person’s cover page.

     

    (iv) Shared power to dispose or to direct the disposition of:

     

    See response to Item 8 on each Reporting Person’s cover page.

     

    Item 5. Ownership of Five Percent or Less of a Class.

     

    Not applicable.

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

     

    Not applicable.

     

    Item 8. Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9. Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10. Certification.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a–11.

     

     
     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: August 8, 2024

     

      BK TL21 LLC.
         
      By: /s/ Bradley Keywell
      Name:  Bradley Keywell
      Title: Manager

     

      /s/ Bradley Keywell
      Bradley Keywell

     

     

     

    Get the next $TEM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TEM

    DatePrice TargetRatingAnalyst
    4/21/2025$60.00Buy
    BTIG Research
    2/25/2025$50.00 → $55.00Overweight → Neutral
    Analyst
    2/12/2025Outperform → Mkt Perform
    William Blair
    2/5/2025$58.00 → $74.00Buy
    TD Cowen
    12/13/2024$60.00Outperform
    Wolfe Research
    12/9/2024$74.00Buy
    Guggenheim
    11/11/2024$45.00 → $65.00Buy → Hold
    Stifel
    10/2/2024$45.00 → $60.00Buy → Neutral
    BofA Securities
    More analyst ratings

    $TEM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Tempus to Participate in TD Cowen's 4th Annual Tools/Dx Revolution Conference

      Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, will participate in TD Cowen's/Securities' 4th Annual Tools/Dx Revolution conference. The event is taking place on June 22 - 25, 2025, in Dana Point, California. Jim Rogers, Chief Financial Officer of Tempus, will join the panel "Acing AI – How To Play The Platforms" on June 23. About Tempus Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world's largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provid

      6/17/25 8:30:00 AM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology
    • Tempus Announces Collaboration with Northwestern University's Abrams Research Center on Neurogenomics to Leverage AI for Alzheimer's Disease Research

      Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a collaboration with The Abrams Research Center on Neurogenomics at Northwestern University Feinberg School of Medicine. This multi-year collaboration aims to harness AI for rapid discovery and innovation in Alzheimer's disease research. The collaboration leverages Tempus' AI-powered data analytics platform, Lens, to analyze and restructure the Center's repository of genomic data. Together, the Center and Tempus teams will work to uncover genomic patterns that have the potential to advance the understanding of Alzheimer's disease, investigate the ge

      6/12/25 8:30:00 AM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology
    • Tempus Introduces xM, An Assay to Monitor Immunotherapy Response for Patients with Advanced Cancers

      Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced xM for treatment response monitoring (TRM), a liquid biopsy assay intended to detect molecular response to immune-checkpoint inhibitor (ICI) therapy in advanced solid tumors. xM for TRM is the newest addition to Tempus' growing portfolio of sensitive assays for monitoring molecular response and minimal residual disease (MRD). It is currently available for research use only, with clinical availability expected later this year. In 2023, an estimated 56.55% of patients with advanced or metastatic cancers were eligible for ICIs, with a corresponding est

      6/2/25 8:30:00 AM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology

    $TEM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Tempus Ai, Inc. exercised 9,218,800 in-the-money shares at a strike of $2.00 and bought $17,745,000 worth of shares (3,500,000 units at $5.07) (SEC Form 4)

      4 - Tempus AI, Inc. (0001717115) (Reporting)

      8/20/24 4:17:55 PM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology

    $TEM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CEO and Chairman Lefkofsky Eric P sold $34,876,062 worth of shares (500,000 units at $69.75) (SEC Form 4)

      4 - Tempus AI, Inc. (0001717115) (Issuer)

      6/20/25 4:15:41 PM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology
    • EVP & Chief Admin & Legal Off Phelps Erik sold $3,723,634 worth of shares (51,317 units at $72.56), decreasing direct ownership by 34% to 97,779 units (SEC Form 4)

      4 - Tempus AI, Inc. (0001717115) (Issuer)

      6/18/25 4:15:21 PM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology
    • EVP and General Counsel Polovin Andrew sold $102,641 worth of shares (1,423 units at $72.13), decreasing direct ownership by 1% to 137,454 units (SEC Form 4)

      4 - Tempus AI, Inc. (0001717115) (Issuer)

      6/18/25 4:15:16 PM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology